Andrew Kochan is a Sherman Oaks, California based physiatrist who is specialized in Pain Management (PM&R). Active license number of Andrew Kochan as Pain Management (PM&R) is G36928 in California.
Andrew Kochan provides a high level of care, either as a primary physician or consultant, for patients experiencing problems with acute, chronic or cancer pain in both hospital and ambulatory settings. Patient care needs may also be coordinated with other specialists.
Complete Profile:
Andrew Kochan speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
Specialization:
Pain Management (PM&R)
Credentials:
MD
Gender:
Male
Practice Address:
4835 Van Nuys Blvd, Suite 100, Sherman Oaks, California, 91403-2109
Phone:
818-995-9331
Fax:
818-995-9334
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1720206881
NPI Enumeration Date:
23 Apr, 2007
NPI Last Update On:
09 Jul, 2007
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Andrew Kochan are as mentioned below.
License Number
Specialization
State
Status
G36928
Pain Management
California
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
8744 Paso Robles Ave, Northridge, California
Zip:
91325-3222
Phone Number:
818-995-9331
Fax Number:
818-995-9334
Patients can reach Andrew Kochan at 4835 Van Nuys Blvd, Suite 100, Sherman Oaks, California or can call to book an appointment on 818-995-9331. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 14 July, 2025.